Compare Novo Nordisk A/S (NVO) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Ultra Short Bond ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Vanguard Ultra Short Bond ETF trades at $49.71. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Vanguard Ultra Short Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | VUSB | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $71.70 | $50.03 |
52-Week Low | $35.29 | $49.60 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VUSB trades at $49.70, up 0.02% on the day, with a bullish technical signal driven by positive momentum indicators. The ETF offers a yield of approximately 4.35%, positioning it as an alternative to money-market funds. Recent dividend payments include $0.18 in April 2026 and $0.17 in May 2026, with another $0.18 scheduled for July 2026.
The outlook for VUSB is supported by potential Federal Reserve rate increases enhancing short-term bond appeal, but risks include credit and duration exposure. The ETF remains a conservative income vehicle amid a non-inverted yield curve, though its technicals show mixed signals with overbought short-term RSI.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
